AUS
NZ
UK
CA
USA
IND
Highlights
- PainChek teams up with Eldermark to grow US market reach
- Integration to deliver AI-driven pain assessments in real-time
- FDA clearance to unlock full-scale sales rollout
PainChek (ASX:PCK) has entered a strategic partnership with Eldermark Software, a long-standing US-based provider of senior living technology solutions, as it accelerates plans to grow its presence in the lucrative American healthcare market.
This new collaboration establishes Eldermark as a non-exclusive reseller and integration partner for PainChek’s Adult app. Designed to address the needs of those in long-term residential care, the app offers AI-driven pain assessment tools using facial recognition technology—delivering real-time analysis and supporting effective pain management.
The agreement, which runs on a 12-month rolling basis, also ensures that PainChek’s software platform will be directly embedded within Eldermark’s care management system. This move is expected to streamline access for Eldermark clients, enabling seamless adoption of the technology across its user network of more than 116,000 clients in the US and Canada.
Sales under the agreement will officially commence once PainChek receives De Novo clearance from the US Food and Drug Administration (FDA), a critical regulatory milestone the company is actively pursuing.
The innovative PainChek app has already gained regulatory approval in other markets and is recognised as the world’s first medical device using smart algorithms to assess and manage pain for individuals who may have difficulty self-reporting. Available on smartphones and tablets, the app employs a standardised numerical rating scale combined with facial recognition AI—empowering caregivers with enhanced tools to deliver more precise and compassionate care.
Commenting on the development, PainChek CEO Philip Daffas described the Eldermark agreement as a pivotal step in expanding the company’s US market footprint, stating it underscores a broader commitment to adopting smart technologies in aged care settings. Eldermark’s CEO Jaime Ojeda echoed the sentiment, citing strong alignment with their mission to provide next-gen tools that elevate caregiving standards.
As investors continue to show growing interest in innovative medtech firms, PainChek’s momentum positions it favourably in discussions about future ASX200 index inclusions. The company’s forward-looking partnerships and global expansion strategies may offer significant long-term value to stakeholders.
Moreover, for those interested in dividend-yielding opportunities, tracking emerging tech players like PainChek alongside established ASX dividend stocks could offer an insightful view into Australia’s evolving equity landscape.
As the US healthcare market places increasing emphasis on digital transformation and quality of life improvements in aged care, PainChek’s advanced platform stands out as a timely and impactful solution poised for broader adoption.
